In a report issued on May 5, Daniel Busby from RBC Capital maintained a Hold rating on Pfizer (PFE), with a price target of $43.00. The company’s shares closed last Thursday at $39.19.
According to TipRanks.com, Busby is a 1-star analyst with an average return of -4.7% and a 38.5% success rate. Busby covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Pacira Pharmaceuticals, and Amneal Pharmaceuticals.
Pfizer has an analyst consensus of Hold, with a price target consensus of $42.30, a 9.9% upside from current levels. In a report released yesterday, Mizuho Securities also downgraded the stock to Hold with a $42.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $43.08 and a one-year low of $31.61. Currently, Pfizer has an average volume of 29.46M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
